about
Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, uIntermediate survival and predictors of death after surgical ventricular restorationMeta-Analysis of Individual Patient Data of Sodium Bicarbonate and Sodium Chloride for All-Cause Mortality After Coronary Angiography.Pre-procedural bioimpedance vectorial analysis of fluid status and prediction of contrast-induced acute kidney injury.Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis.Shortened head-up tilt testing potentiated with sublingual nitroglycerin in patients with unexplained syncope.Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis.[Contrast-induced nephropathy: the VIKISAFE study group statement].Therapeutic strategies, immediate and mid-term outcomes in non-ST-segment elevation acute coronary syndromes with respect to age: a single-center registry of 488 consecutive patients.Impact of time from symptom onset to drug administration on outcome in patients undergoing glycoprotein IIb-IIIa facilitated primary angioplasty (from the EGYPT cooperation).Statin treatment before percutaneous cononary intervention.Impact of Rosuvastatin in Contrast-Induced Acute Kidney Injury in the Elderly: Post Hoc Analysis of the PRATO-ACS Trial.Preprocedural score for risk of contrast-induced nephropathy in elective coronary angiography and intervention.Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation.Usefulness of dobutamine Tc-99m sestamibi-gated single-photon emission computed tomography for prediction of left ventricular ejection fraction outcome after coronary revascularization for ischemic cardiomyopathy.Low-dose dobutamine nitrate-enhanced technetium 99m sestamibi gated SPECT versus low-dose dobutamine echocardiography for detecting reversible dysfunction in ischemic cardiomyopathy.Impact of multivessel disease on myocardial perfusion and survival among patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitors.Impact of preprocedural TIMI flow on myocardial perfusion, distal embolization and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors.Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention.Impact of advanced age on myocardial perfusion, distal embolization, and mortality patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors.Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation.[Sirolimus-eluting stent for in-stent restenosis treatment: single center results in an unselected study population].Impact of hypertension on distal embolization, myocardial perfusion, and mortality in patients with ST segment elevation myocardial infarction undergoing primary angioplasty.Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction.Early high-dose rosuvastatin and cardioprotection in the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS) study.Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and AntiplEarly abciximab administration in acute myocardial infarction treated with primary coronary intervention.Markers of myocardial reperfusion as predictors of left ventricular function recovery in acute myocardial infarction treated with primary angioplasty.Use of 99mTc-sestamibi gated SPECT to assess the influence of anterograde flow before primary coronary angioplasty on tissue salvage and functional recovery in acute myocardial infarction.Acute hemodynamic effects of intravenous diperdipine, a new dihydropyridine derivative, in coronary heart disease.Feasibility of an accurate assessment of myocardial salvage by comparing functional and perfusion abnormalities in post-reperfusion gated SPECTPharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus statusHigh-Dose Atorvastatin on the Pharmacodynamic Effects of Double-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary InterventionsSynergistic action of postextrasystolic potentiation and diperdipine on left ventricular wall motion abnormalities in coronary heart disease[Efficacy of intravenous and per os propafenone in the ambulatory treatment of recent-onset atrial fibrillation]Abnormalities of left ventricular shape in patients with stable anginaEffects of diltiazem on postextrasystolic potentiation in coronary heart disease patientsDiverging effects of postextrasystolic potentiation on left ventricular segmental wall motion in coronary heart diseaseBlood velocity in the coronary artery circulation: relation to thromboxane A2 levels in coronary sinus in patients with angiographically normal coronary arteries
P50
Q28191990-684E4AED-C45A-42AF-BDC8-A1A19D378C54Q28216418-BE08D615-C02F-412C-8FA7-E102969A2F1AQ30245231-F816271F-79EC-4AE3-A3FB-65D777B83791Q30457440-1C3C57F2-93A2-43E0-8031-C820DB073C07Q31155246-9B47FAE6-1C85-4525-A96A-30EB7DEB416BQ33175575-60359154-7B19-4C47-9694-798911BBA727Q34022160-A913E38A-2FF9-4225-BADF-9C80F04B9160Q34637849-2F40FD5B-0C72-427D-8AF1-307B6E3253CBQ35878091-178C21AE-353E-4AF8-94D0-2655B9A221B7Q38966136-AA6B3AFD-E49E-4589-B5E3-4FA1ADDC9451Q41374557-BEDA6ED1-6041-407C-9ACC-6ECB636BDD7DQ41452418-27904327-ED64-4C68-86AE-3CD8AEBCEE7FQ43158465-9CB4F411-0301-4A6F-8CC5-9B6D2EADCCB2Q43742929-23A930D6-ECEB-4A0B-B35E-58AD813AA141Q43927896-E8927C7C-9CCD-4968-8F35-2C2CB857C932Q44089190-DE57C06D-4485-40F8-B3B8-0C7337560963Q44597117-A6B6A433-CBB7-4DE2-9A2A-65C38C53CF38Q44805575-7ED92D3E-750D-4FD5-88D5-10C9C156677AQ44916106-9D731787-4C9C-4513-89F8-4EC74407D29EQ46290025-29620313-1F45-4021-BEA0-07AF00231296Q46429842-9CF6AAC7-98FA-4E69-9985-15D9FF032BB0Q46775055-7E963B9B-7EE4-4343-9470-54B397FF41F3Q46799334-65FB8FF0-6F98-487F-8B34-5FBDB8211584Q48939100-4FB9CC42-98DD-4FF7-BCE0-22CC87079FE8Q50786610-195A7677-9507-48F4-8BDF-9BF30B9E9E01Q50849308-D17BCA6B-00AB-495D-8582-1A7ADA944964Q50849807-A0DF0B0D-757D-4718-BD71-81494CF8F865Q51448293-D591794A-58CA-459D-8633-321A8921D18DQ53599462-E90C4780-1662-406D-8534-7B36A96143FDQ53619586-8C8E7877-54CE-4F3B-801D-8A890ED7A274Q54300756-3D59B0C7-7291-4114-8397-5C1FD779CA08Q57988243-14A3A23F-84E4-4AE6-93CA-50D67B06028AQ62607023-5EDC5F17-FFC6-4EDA-8079-CC19A2823B95Q62607026-13DECCE3-8DCA-4C20-86DE-3C4DFD95E577Q67533217-4475F050-E8B4-4108-A121-6576429367F4Q67923747-979F8379-FC2A-4BF1-9FC5-1D87D2F0C982Q68775012-C8BA66FC-C65B-4F76-A467-F08C5A7AE7A6Q68859168-D3CBE79D-2F05-456B-A406-BBE5DBD33E40Q69007433-A08CC457-023D-4054-B938-FE95C978FD5BQ69054249-B89FCB07-D71D-439F-8CB5-F17DCC309655
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mauro Maioli
@ast
Mauro Maioli
@en
Mauro Maioli
@es
Mauro Maioli
@nl
Mauro Maioli
@sl
type
label
Mauro Maioli
@ast
Mauro Maioli
@en
Mauro Maioli
@es
Mauro Maioli
@nl
Mauro Maioli
@sl
prefLabel
Mauro Maioli
@ast
Mauro Maioli
@en
Mauro Maioli
@es
Mauro Maioli
@nl
Mauro Maioli
@sl
P106
P31
P496
0000-0001-8856-9813